Journal of Pharmacological Sciences
Online ISSN : 1347-8648
Print ISSN : 1347-8613
ISSN-L : 1347-8613
Forum Minireviews
Drug Discovery for Overcoming Chronic Kidney Disease (CKD):
Prolyl-Hydroxylase Inhibitors to Activate Hypoxia-Inducible Factor (HIF) as a Novel Therapeutic Approach in CKD
Tetsuhiro TanakaMasaomi Nangaku
Author information

2009 Volume 109 Issue 1 Pages 24-31


Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor composed of an oxygen-dependent α-subunit and constitutively expressed β subunit, which plays a central role in cellular adaptation to hypoxia by transcriptionally upregulating its target genes involved in angiogenesis, erythropoiesis, glycolysis, and so on. Recent studies demonstrated that hypoxia in the tubulointerstitium is involved in the pathology of progressive renal diseases and that HIF, which is activated in experimental kidney diseases, may serve to protect tubulointerstitium from the ischemic insult. The expression of HIF α-chains is post-translationally regulated and hydroxylation at one or two of the conserved proline residues by prolyl-hydroxylase domains (PHDs) is a critical step for the oxygen-dependent recruitment of the von Hippel–Lindau gene product (pVHL), a recognition component of the E3 ubiquitin ligase complex, and degradation of HIF-α. Conversely, modalities to inhibit the enzymatic activities of PHDs have been shown to activate HIF irrespective of oxygenation status and are regarded as candidate targets of pharmacological approaches against chronic kidney diseases characterized by hypoxia.

Information related to the author
© The Japanese Pharmacological Society 2009
Previous article Next article